Comparative Analysis of Glucuronoxylomannogalactan and Glucuronoxylomannan Antibody Responses and Their Associations With Cryptococcal Disease Status in People With HIV
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf366 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Hyunah Yoon und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA. Hauptthemen laut MEDLINE: HIV Infections, Antibodies, Fungal, Cryptococcosis, Polysaccharides. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Health, National Institute of Allergy and Infectious Diseases, NIAID NIH HHS.
Abstract (Originalsprache)
Background
Cryptococcosis remains a major cause of mortality in people with HIV (PWH). While glucuronoxylomannan-binding immunoglobulin G (GXM-IgG) levels have been associated with disease status and survival, the clinical significance of glucuronoxylomannogalactan-binding IgG (GXMGal-IgG) has not been investigated.
Methods
We analyzed serological data from 2 previously reported cohorts of PWH: a prospective asymptomatic South African cohort (67 cryptococcal antigen [CrAg] positive, 130 CrAg negative), and a Vietnamese case-control cohort (30 with symptomatic cryptococcal meningitis [CM], 30 without), both followed for mortality for 6 months. Serum/plasma GXMGal-IgG levels were quantified by enzyme-linked immunosorbent assay and compared to previously reported GXM-IgG levels. Logistic regression adjusted for age, sex, and CD4 count examined associations between antibody levels and CrAg positivity or CM status, while Cox proportional hazards models adjusted for CD4 count estimated associations with time to mortality.
Results
Higher GXMGal-IgG was associated with CrAg positivity (odds ratio, 1.64; 95% confidence interval [CI], 1.14–2.36), not CM status. Among individuals with asymptomatic cryptococcal antigenemia, higher GXMGal-IgG trended toward higher survival (hazards ratio, 0.67; 95% CI, .41–1.09), but this was not statistically significant and no significant survival benefit was observed for those with CM.
Conclusions
GXMGal-IgG was associated with CrAg positivity and showed a modest trend toward survival for individuals with asymptomatic cryptococcal antigenemia but had limited predictive value for CM or mortality. These findings in antigenemia largely parallel previous observations for GXM-IgG, although associations observed were generally weaker. Further studies are needed to clarify the immune response to GXMGal and its potential diagnostic or prognostic significance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
- Department of Microbiology and Immunology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
- Wits Mycology Division, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Institute for Infection and Immunity, City St George's, University of London, London, United Kingdom.
- Department of Clinical Microbiology and Infection, Royal Devon and Exeter University Hospital NHS Trust, Exeter, United Kingdom.
- National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.
ORCID-Profile: Hyunah Yoon, Caroline T Tiemessen, Joseph N Jarvis, Elias Barbosa da Silva-Junior, Israel Diniz-Lima, Liise-Anne Pirofski
Förderung
- National Institute of Health
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- UK Government
- National Institute for Health and Care Research
Zitieren
APA
Yoon, H., Nakouzi, A. S., Wake, R. M., Day, J., Tiemessen, C. T., Govender, N. P., Jarvis, J. N., da Silva-Junior, E. B., Diniz-Lima, I., Decote-Ricardo, D., Previato, J. O., Mendonça-Previato, L., Harrison, T. S., Freire-de-Lima, C. G., & Pirofski, L. A. (2025). Comparative Analysis of Glucuronoxylomannogalactan and Glucuronoxylomannan Antibody Responses and Their Associations With Cryptococcal Disease Status in People With HIV. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf366
Vancouver
Yoon H, Nakouzi AS, Wake RM, Day J, Tiemessen CT, Govender NP, et al. Comparative Analysis of Glucuronoxylomannogalactan and Glucuronoxylomannan Antibody Responses and Their Associations With Cryptococcal Disease Status in People With HIV. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf366
BibTeX
@article{Yoon2025,
author = {Yoon, Hyunah and Nakouzi, Antonio S and Wake, Rachel M and Day, Jeremy and Tiemessen, Caroline T and Govender, Nelesh P and Jarvis, Joseph N and da Silva-Junior, Elias Barbosa and Diniz-Lima, Israel and Decote-Ricardo, Debora and Previato, Jose Osvaldo and Mendonça-Previato, Lucia and Harrison, Thomas S and Freire-de-Lima, Celio Geraldo and Pirofski, Liise-Anne},
title = {Comparative Analysis of Glucuronoxylomannogalactan and Glucuronoxylomannan Antibody Responses and Their Associations With Cryptococcal Disease Status in People With HIV},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf366}
}
EUVIMED